×
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
NASDAQ:CGTX

Cognition Therapeutics News Headlines

$1.84
+0.20 (+12.20%)
(As of 06/24/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.55
$1.95
50-Day Range
$1.50
$3.15
52-Week Range
$1.50
$13.80
Volume
102,607 shs
Average Volume
28,447 shs
Market Capitalization
$41.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.33
Get Cognition Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CGTX and its competitors with MarketBeat's FREE daily newsletter.

CGTX Media Mentions By Week

CGTX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CGTX
News Sentiment

0.54

0.39

Average
Medical
News Sentiment

CGTX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CGTX Articles
This Week

3

1

CGTX Articles
Average Week



CGTX Stock News Headlines Today

SourceHeadline
seekingalpha.com logoCognition stock rises as dosing begins in phase 2 study of CT1812 for dementia
seekingalpha.com - June 23 at 5:19 PM
finance.yahoo.com logoCognition Therapeutics Doses First Patient with Dementia with Lewy Bodies in Phase 2 Clinical Study of CT1812
finance.yahoo.com - June 23 at 8:38 AM
finance.yahoo.com logoCognition Therapeutics Doses First Patient with Dementia with Lewy Bodies in Phase 2 Clinical Study of CT1812
finance.yahoo.com - June 23 at 8:38 AM
MarketBeat logoCognition Therapeutics, Inc. (NASDAQ:CGTX) Short Interest Update
americanbankingnews.com - June 17 at 3:59 AM
finance.yahoo.com logoCognition Therapeutics Announces Presentation at the Upcoming JMP Securities Life Sciences Conference
finance.yahoo.com - June 8 at 10:54 AM
finance.yahoo.com logoCognition Therapeutics Announces Presentation at the Upcoming JMP Securities Life Sciences Conference
finance.yahoo.com - June 8 at 10:53 AM
finance.yahoo.com logoCognition Therapeutics to Host Virtual KOL Symposium on Dry Age-related Macular Degeneration and the Potential for Sigma-2 Modulation
finance.yahoo.com - June 2 at 4:59 PM
finance.yahoo.com logoCognition Therapeutics to Participate in H.C. Wainwright Global Investment Conference
finance.yahoo.com - May 13 at 8:45 AM
seekingalpha.com logoCognition Therapeutics GAAP EPS of $0.17 beats by $0.46
seekingalpha.com - May 11 at 8:17 AM
finance.yahoo.com logoCognition Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
finance.yahoo.com - May 11 at 8:17 AM
finance.yahoo.com logoCognition Therapeutics to Report First Quarter 2022 Financial Results on May 11, 2022
finance.yahoo.com - May 4 at 6:36 PM
finance.yahoo.com logoCORRECTION -- Cognition Therapeutics to Report First Quarter 2022 Financial Results on May 11, 2022
finance.yahoo.com - May 4 at 6:36 PM
finance.yahoo.com logoCognition Therapeutics Presented Preclinical Findings Showing that Sigma-2 Receptor Modulators Rescue Trafficking Deficits in Retinal Pigment Epithelial Cells in Model of Dry AMD
finance.yahoo.com - May 3 at 10:27 AM
finance.yahoo.com logoInsiders who bought in the last 12 months lose an additional US$189k as Cognition Therapeutics, Inc. (NASDAQ:CGTX) drops to US$63m
finance.yahoo.com - May 2 at 1:34 PM
finance.yahoo.com logoCognition Therapeutics to Present Preclinical Results Demonstrating Therapeutic Potential for Sigma-2 Receptor Modulators in Dry Age-Related Macular Degeneration
finance.yahoo.com - April 25 at 8:56 PM
nz.finance.yahoo.com logoCognition Therapeutics Announces Participation in B. Riley Securities 2022 Virtual Neuro & Ophthalmology Conference
nz.finance.yahoo.com - April 25 at 10:55 AM
benzinga.com logoLadenburg Thalmann Initiates Coverage On Cognition Therapeutics with Buy Rating, Announces Price Target of $10
benzinga.com - April 22 at 9:26 AM
finance.yahoo.com logoCognition Therapeutics Announces Participation in 21st Annual Needham Virtual Healthcare Conference
finance.yahoo.com - April 6 at 12:32 PM
seekingalpha.com logoCognition Therapeutics GAAP EPS of -$3.13 misses by $2.64
seekingalpha.com - March 30 at 9:17 AM
finance.yahoo.com logoCognition Therapeutics Reports Year End 2021 Financial Results and Provides Business Update
finance.yahoo.com - March 30 at 9:17 AM
bizjournals.com logoCognition Therapeutics cofounder joins West Coast biopharma firm
bizjournals.com - March 23 at 4:26 PM
benzinga.com logoHow To Attend Cognition Therapeutics Q4 2021 Earnings Conference Call
benzinga.com - March 22 at 6:34 PM
finance.yahoo.com logoCognition Therapeutics to Report Fourth Quarter and Full Year 2021 Results
finance.yahoo.com - March 22 at 8:37 AM
benzinga.com logoCognition Therapeutics to Present Analyses from Clinical Studies of CT1812 in Patients with Alzheimer's Disease at AD/PD 2022
benzinga.com - March 11 at 11:16 PM
finance.yahoo.com logoCognition Therapeutics to Present Analyses from Clinical Studies of CT1812 in Patients with Alzheimer’s Disease at AD/PD 2022
finance.yahoo.com - March 10 at 12:12 PM
finance.yahoo.com logoCognition Therapeutics Announces Participation in March Investment Conferences
finance.yahoo.com - March 8 at 10:24 AM
finance.yahoo.com logoCognition Therapeutics to Participate in Panel during the BIO CEO & Investor Conference on the Development of Neurodegenerative Therapeutics
finance.yahoo.com - February 8 at 8:45 AM
bizjournals.com logoCEO talks Cognition Therapeutics' strategy for 2022 and beyond
bizjournals.com - January 24 at 5:49 PM
seekingalpha.com logoCognition Therapeutics highlights upcoming milestones with Alzheimer’s in focus
seekingalpha.com - January 11 at 1:39 PM
finance.yahoo.com logoCognition Therapeutics Provides Update on Corporate and Pipeline Progress and Reviews Goals for 2022
finance.yahoo.com - January 10 at 12:35 PM
finance.yahoo.com logoCompanies Like Cognition Therapeutics (NASDAQ:CGTX) Are In A Position To Invest In Growth
finance.yahoo.com - January 8 at 8:29 AM
finance.yahoo.com logoCognition Therapeutics Receives Grant from Michael J. Fox Foundation to Support Development of Sigma-2 Receptor Modulator for Parkinson’s Disease
finance.yahoo.com - January 4 at 10:22 AM
finance.yahoo.com logoCognition Therapeutics to Participate in Next-Generation Alzheimer’s Disease Panel at Virtual Biotech Showcase on January 11, 2022
finance.yahoo.com - December 21 at 8:28 AM
finance.yahoo.com logoCognition Therapeutics to Host Virtual R&D Symposium December 7 on Dementia with Lewy Bodies and the Potential for Sigma-2 Modulation
finance.yahoo.com - November 30 at 12:35 PM
nasdaq.com logoCognition Therapeutics, Inc. Common Stock (CGTX)
nasdaq.com - November 23 at 7:49 PM
finance.yahoo.com logoCognition Therapeutics Reports Third Quarter Financial Results and Company Highlights
finance.yahoo.com - November 18 at 8:20 AM
finance.yahoo.com logoCognition Therapeutics Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in connection with Initial Public Offering
finance.yahoo.com - November 15 at 9:44 AM
nz.finance.yahoo.com logoCognition Therapeutics Adds Public Company Financial and Operational Expertise to Board of Directors with Appointment of Ellen B. Richstone
nz.finance.yahoo.com - November 3 at 8:38 AM
finance.yahoo.com logoCognition Therapeutics, Inc. (CGTX)
finance.yahoo.com - October 27 at 12:37 AM
finance.yahoo.com logoNotable Cognition Therapeutics Insider Trades $2.3M In Company Stock
finance.yahoo.com - October 25 at 8:22 AM
Get Cognition Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CGTX and its competitors with MarketBeat's FREE daily newsletter.

This page (NASDAQ:CGTX) was last updated on 6/26/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.